Edasalonexent Treatment in Young Boys with Duchenne Muscular Dystrophy is Associated with Age-Normative Growth and Normal Adrenal Function

Erika L. Finanger, MD1; Richard Finkel, MD2; Krista Vandenborne, PT, PhD3; H Lee Sweeney, PhD3; Gihan Tennekoon, MBBS, MRCS, LCRP4; Perry Shieh, MD, PhD5; Sabrina W. Yum, MD4; Maria Mancini, MHP6; James MacDougall, PhD6; Joanne Donovan, MD, PhD6

1Oregon Health Sciences University, Portland, OR; 2Nemours Children's Health System, Orlando, FL; 3University of Florida Health, Gainesville, FL; 4The Children's Hospital of Philadelphia, Philadelphia, PA; 5University of California, Los Angeles, Los Angeles, CA; 6Catabasis Pharmaceuticals, Boston, MA

MDA Clinical and Scientific Conference, March 2020
Erika Finanger received research support and honoraria from Catabasis Pharmaceuticals, Inc.

The clinical trial was sponsored by Catabasis Pharmaceuticals, Inc.

Krista Vandenborne, H. Lee Sweeney, Erika Finanger, Gihan Tennekoon, Perry Shieh, and Sabrina Yum received research support from Catabasis. H. Lee Sweeney, Erika Finanger, and Perry Shieh received honoraria from Catabasis.

Maria Mancini, James MacDougall, and Joanne Donovan are employees or consultants of Catabasis and may hold stock in Catabasis.

Edasalonexent is an investigational agent that is not approved in any territory.
Activation of NF-κB in Duchenne Muscular Dystrophy Is a Key Factor in Disease Progression

No Dystrophin + Mechanical Stress

Chen et al., Neurology 2005 65: 826
Fiorillo et al., Physiol Genomics 2018 50:735
Fiorillo et al., Physiol Genomics 2018 50:735
Kumar et al., FASEB J 2003 17:386
Akima et al., Neuromuscul Disord 2012 22: 16
Edasalonexent Inhibits NF-κB, A Key Driver of Muscle Disease in DMD

- Edasalonexent is an orally-administered small molecule

- Edasalonexent has a unique pharmacological profile that inhibits NF-κB better than its individual components

Edasalonexent Synergistically Inhibits NF-κB (p65) in Adult Humans

Edasalonexent is a Unique Molecule Delivering Salicylic Acid and DHA into Cells by using SMART Linker Technology


* p<0.005
Inhibition of NF-κB Slowed Disease Progression in Preclinical Models of DMD

Genetic disruption of NF-κB slowed disease progression in \textit{mdx} mice
- \textit{mdx}/p65+/- mice with 50% reduction in NF-κB activity

Pharmacological inhibition of NF-κB also slowed disease progression in animal models of DMD
- Oral administration of edasalonexent analog (CAT-1041) reduced muscle inflammation and improved function in \textit{mdx} mice and GRMD dog

\textbf{Reduced Muscle Fibrosis (Gastrocnemius)}
\textit{mdx} \textit{WT} vs \textit{mdx} \textit{p65+/-}

\textbf{Reduced Muscle Fibrosis (Quadriceps)}

\textbf{Improved Muscle Function (Diaphragm Specific Force)}

\textbf{Mean} + \textbf{SEM}

\textit{Hammers, et al. JCI Insight 2016 1(21): e90341}
Design of MoveDMD®, a Phase 1/2 Trial with Open-Label Extension

- **Study Objectives**
  - Safety and PK in pediatric patients with DMD
  - Proof of concept using MRI to assess changes in muscle health
  - Long-term safety and effects on age-appropriate functional measures to enable design of Phase 3 study

- **Study Population**
  - Age 4 up to 8th birthday not currently being treated with corticosteroids
  - Able to perform timed function tests and MRI

- **Design**
  - Phase 1: 1-week open-label to assess safety and PK, with initial assessments of function and MRI
  - Off-treatment period of ~6 months prior to Phase 2
  - Phase 2: 12-week placebo-controlled period of 67 mg/kg and 100 mg/kg doses of edasalonexent
  - Open-label extension up to 150 weeks

- **Prespecified Analysis Plan**
  - 12-week placebo controlled period evaluated MRI T2, North Star Ambulatory Assessment, timed-function tests, and safety
  - Additional comparison of rates of change during off-treatment control period versus on edasalonexent treatment
Experience with Edasalonexent Demonstrates Ability of 4 to 7-year-old Boys with DMD to Take Soft-gel Capsules in Clinical Trials

- **Assessed ability to swallow capsules at screening visit**
  - As part of the eligibility criteria, Phase 2 MoveDMD trial required boys to demonstrate ability to swallow at least one capsule size in order to meet eligibility

- **In the Phase 2 MoveDMD trial, 97% of boys screened were able to swallow capsules**

- **Edasalonexent capsules were well-accepted in boys with DMD**
  - Site experience, clinical trial personnel confidence and initial capsule size presentation had the most significant impact in selection.
  - Age did not appear to be a major determinant of ability to take capsules
  - Soft-gel capsules were successfully used in this phase 2 clinical trial of boys as young as 4 years with appropriate support

- **Total of 24 of 31 enrolled (77%) started on the smaller, 100 mg capsules with most transitioning to the larger 250 mg capsule by Week 24**
- **Compliance was high (~98%) with no discontinuations due to capsule burden**
### In Phase 2 MoveDMD Trial and Open-Label Extension:
**Safety: Edasalonexent was Well-Tolerated**

- **Well tolerated for up to 150 weeks**
- **Majority of adverse events mild in nature**
  - Most common related adverse event was diarrhea, generally mild and transient
  - No serious adverse events on treatment (one on placebo)
- **No adverse trends in chemistry and hematology**

<table>
<thead>
<tr>
<th>Treatment-Related Adverse Events &gt;5%</th>
<th>Edasalonexent Overall (N=31)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>System Organ Class/ Preferred Term</strong></td>
<td>n %</td>
</tr>
<tr>
<td>Subjects with any treatment-emergent adverse event</td>
<td>31 (100%)</td>
</tr>
<tr>
<td>Subjects with any treatment-emergent adverse event related to study treatment</td>
<td>19 (61.3%)</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>16 (51.6%)</td>
</tr>
<tr>
<td>Abdominal pain upper</td>
<td>7 (22.6%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>3 (9.7%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3 (9.7%)</td>
</tr>
<tr>
<td>Abdominal discomfort</td>
<td>2 (6.5%)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>2 (6.5%)</td>
</tr>
<tr>
<td>Faecal incontinence</td>
<td>2 (6.5%)</td>
</tr>
<tr>
<td>Faeces soft</td>
<td>2 (6.5%)</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>4 (12.9%)</td>
</tr>
</tbody>
</table>
There was no evidence of adrenal insufficiency for up to 150 weeks, with no clinically significant changes in either cortisol or ACTH.
 Decreased Bone Density and Bone Strength

- Both myopathy and GC therapy lead to reduced bone density and bone strength in DMD.
- Increased fracture risk is apparent in boys with DMD with or without GC*.
  - In this retrospective study, fracture incidence in glucocorticoid naïve boys was 2.5%/year.
  - In the same study, fracture incidence in first 2 years of glucocorticoids was 11.6%.
- In MoveDMD, fracture incidence was 3.2%/year with neither long bone nor minimal trauma fractures.

Potential for Bone Preservation with Edasalonexent

- Unlike glucocorticoids (GC), edasalonexent treatment in a mdx mouse model preserves bone length and bone density.

Donovan 2019 Bone Symposium oral presentation, Salzburg, Austria

Boys on edasalonexent grew similarly to growth curves for unaffected boys up to 150 weeks:
- Weight increased by an average of 4.5 lbs/year
- Height increased by an average of 1.9 inches/year

BMI is typically elevated in these boys and on edasalonexent treatment, BMI trended down.

## z-Scores Compared to CDC Growth Charts

**Weight z-Scores**

**Height z-Scores**

**BMI z-Scores**

Box plot error bars indicate range of values.
Comparison with CDC growth charts: [https://www.cdc.gov/growthcharts/clinical_charts.htm](https://www.cdc.gov/growthcharts/clinical_charts.htm)
In Phase 2 MoveDMD Trial and Open-Label Extension:

**Edasalonexent Demonstrated Clinically Meaningful Slowing of Disease Progression Compared to Off-Treatment Period**

---

**North Star Ambulatory Assessment**

- **Edasalonexent** 100 mg/kg
- **Control Period**

- **Average Rate of Change**

---

**4-Stair Climb**

- **Edasalonexent** 100 mg/kg
- **Control Period**

- **Average Rate of Change**

---

**10-Meter Walk/Run**

- **Edasalonexent** 100 mg/kg
- **Control Period**

- **Average Rate of Change**

---

**Time to Stand**

- **Edasalonexent** 100 mg/kg
- **Control Period**

- **Average Rate of Change**

---

**Sustained stabilization up to 72 weeks on edasalonexent**

Means ± SEM shown. Includes data of all boys initially started on 100 mg/kg dose (n=16) with 11 boys participating through 72 weeks.
In Phase 2 MoveDMD Trial and Open-Label Extension:

**Edasalonexent Improved Rate of Change of MRI T2 Compared to Off-Treatment Control Period**

MRI T2 is tightly correlated with fat fraction and functional measures.

12-week Phase 2 MRI T2 primary endpoint for treated boys compared to boys in the placebo group was directionally positive although not statistically significant.

Following 72 weeks of edasalonexent, the rate of increase in the composite MRI T2 decreased as compared to the rate of increase during the off-treatment control period.

- Early and sustained response in annualized rate of change

**MRI T2: Composite of 5 Lower Leg Muscles**

- Composite of 5 lower leg muscles MRI T2 (soleus, gastrocnemius, anterior and posterior tibialis, peroneals) used to encompass muscles at various stages of disease progression and minimize variability.

Means ± SEM; mixed model comparison with off-treatment period

* Week 12: p=0.002, n=16; Week 24: p=0.004, n=14; Week 36: p=0.032, n=13; Week 48: p=0.018, n=12; Week 72: p=0.052, n=9
Phase 2 MoveDMD Trial Supports Phase 3 Trial Design

- Supportive of Phase 3 clinical trial – the global PolarisDMD trial is fully enrolled across all 8 countries where the trial is active

- Enrolled 131 boys ages 4-7 (up to 8th birthday)
  - Not on corticosteroids for at least 6 months

- 2:1 randomization, 67% of boys receive drug initially, all boys have the option to receive drug after 12 months through GalaxyDMD

- Clinical trial site visits and key assessments every 3 months

- Safety measures including labs every 3 months

- Top-line results expected in Q4 2020

---

**Phase 2 MoveDMD Trial**

**12-month, randomized, double-blind placebo-controlled trial, n=131**

- Edasalonexent 100 mg/kg
- Placebo

**Open-label extension**

- Edasalonexent

**Primary Endpoint**

NCT03703882 and NCT03917719
In the Phase 2 MoveDMD trial, treatment with edasalonexent was well-tolerated and associated with favorable growth patterns without negative impact on bone health or adrenal function.

Edasalonexent has the potential to be disease-modifying in DMD patients and in this Phase 2 trial did not have the adverse effects associated with high-dose steroids.

An ongoing Phase 3 trial of edasalonexent, PolarisDMD, is fully enrolled and is further assessing safety and efficacy in young boys with DMD.
Acknowledgements

- Patients and families
- Patient groups
- ImagingDMD staff
- Site staff
- Catabasis team
- Thanks to PPMD and MDA for generous grant support for patient travel